Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. - Wikidata - wikimedia - TriplyDB

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.

http://www.wikidata.org/entity/Q33419580

about

The clinical implications of gene mutations in chronic lymphocytic leukaemia BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia Know the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemia Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms Targeted therapies in CLL: mechanisms of resistance and strategies for management Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number.A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia Prognostic signature and clonality pattern of recurrently mutated genes in inactive chronic lymphocytic leukemia Specificity and biologic activities of novel anti-membrane IgM antibodies Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo.Initial treatment of CLL: integrating biology and functional status.Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib.Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib.Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study Detection of chromothripsis-like patterns with a custom array platform for chronic lymphocytic leukemia.Chronic lymphocytic leukemia therapy: new targeted therapies on the way Disseminated Cryptococcal Disease in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib.Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients Leukemia cutis in a patient with chronic lymphocytic leukemia presenting as bilateral helical nodules.Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia.Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target.Emerging immunological drugs for chronic lymphocytic leukemia.Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly.Ibrutinib in B lymphoid malignancies.Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide.

P2860

Q26749214-F1AACF41-ED46-4A95-9AD4-28F45EFB805F Q26765624-B19D3D7F-13D1-4B1A-A549-DC0242BAD7B8 Q26775506-649C89A4-9FDC-434D-A755-E639EFA9246A Q26781895-723C3EE8-8B94-4F3D-80C0-A617CA032F9E Q26795594-3AA5616F-F2F8-405F-AF3E-7BF5E2DDCC34 Q27002528-73C90806-C9A4-4722-ABB0-ED6A4058003E Q27025812-77994D4E-5035-4388-8B7B-8CB28F1ACFB2 Q28075504-DF62BC93-5BD8-40F8-AD87-795DFE2D124B Q30243968-B4B0DE57-4974-4C01-81A7-BEF564D0A353 Q30252869-202E3D0B-6B10-4F38-8378-219988E3C444 Q31097476-073DB545-65ED-487C-BFB4-8C08E216077B Q33566747-B720E6A5-E336-49E2-856C-EADC42FA3D91 Q33798525-9FB470CB-4A1B-4652-967F-896D0C473BE6 Q35794593-BA4423B1-43AA-4497-83B3-76414B799211 Q35958056-9F562AAE-336D-4BD3-8D44-F364DCCF5A33 Q36022532-21815659-1E56-458C-B21C-F6C3CC2BF8FE Q36161658-88FB2233-5D1A-422D-974D-17946F226E29 Q36172601-55E0F342-A625-46F7-9EDB-354A4D151590 Q36219647-97DF1299-9119-4554-A892-C57012B31187 Q36253983-D472AE0C-4354-45B8-B915-80053E679DFB Q36337598-FE236D46-1636-483D-BCFC-9D7086795341 Q36437030-EB083087-1CD2-45A2-A427-E1388E1D56FE Q36490049-AA52AFA4-3BBC-4B4E-B38E-27AE4CC02DAF Q36550468-24A9D71D-1D55-48CF-A95B-E2A33D5688F5 Q36759124-8452111F-7A70-4BF5-8813-4C7065445B82 Q36799831-200E806E-5D7D-4445-B4FD-5B1AEBF6850D Q37113544-4C876AA0-5F90-44CA-A23F-F2D9E36C99E8 Q37290270-82CE162B-330F-4CBA-BA2A-CD6EBEC742E4 Q37489992-38227A66-090A-4034-9748-ECF2A75540C4 Q37641245-6CB01746-523A-4B0F-92F1-77D6685B00D7 Q37641736-B906E5A2-9817-4025-B212-1E71A6BD0C13 Q37688589-5733BF8E-A52F-43FB-A654-C8509494C176 Q37697093-BC378F70-A77D-4230-963D-C3F11CA7FE45 Q37742056-F365CF23-BF64-4FB9-B486-01FAAD3DB60F Q38524270-567399F0-A316-4792-8BDC-657DE162612B Q38543771-072BAAF8-2DC2-448B-8319-F9CEE71799C7 Q38544216-5131FDAF-AA9F-4744-9A77-329A41AFA426 Q38545545-40E5A365-D235-4FFA-A590-629351DA4BD2 Q38550810-E7751FE9-9BAA-4C47-B551-32F554D84B08 Q38594364-A6DFCC02-6ADD-4514-BD22-F63C2B9FA5D6

P2860

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.

http://www.wikidata.org/entity/Q33419580

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Ibrutinib for previously untre ...... : a phase 2, single-arm trial.

@ast

Ibrutinib for previously untre ...... : a phase 2, single-arm trial.

@en

type

label

Ibrutinib for previously untre ...... : a phase 2, single-arm trial.

@ast

Ibrutinib for previously untre ...... : a phase 2, single-arm trial.

@en

prefLabel

Ibrutinib for previously untre ...... : a phase 2, single-arm trial.

@ast

Ibrutinib for previously untre ...... : a phase 2, single-arm trial.

@en

P1433

Q33419580-E4518CD6-C4FA-40A1-B1D8-9547980B5FCB

P1476

Q33419580-BF6A0166-57D5-4A23-AFBD-84F5907945FC

P2093

Q33419580-052E1A32-B0BD-444F-8A36-6C9523FC8847

Q33419580-0B78B429-C954-4F4E-B9AE-BB861AE60F50

Q33419580-18D6157F-3270-49AF-996B-C1B4C6696EED

Q33419580-2263EC3C-9F6E-44E0-AF10-2006BE361D70

Q33419580-27B6AF24-BF74-4B65-BC7A-B9FA90BBF837

Q33419580-287CCE83-0DCC-4B32-AAA8-DB331F97D482

Q33419580-2AF7DCEA-E087-4F90-B6FA-96A65E726767

Q33419580-2FA5A2F7-E538-4772-B6F1-F72CE806EDC0

Q33419580-47E6AA0E-D4A7-46C8-A55B-E6C083FF4D53

Q33419580-4880767E-69E3-4E99-BDD0-45D7D4FF9FD2

P2860

Q33419580-0285F3F9-32BA-4A70-A87F-6E3CA3508978

Q33419580-092F5D0C-82BC-444E-929B-04DAFC1F3272

Q33419580-14CF751C-BB85-4F3E-95DB-21F49DD37C54

Q33419580-17A33667-12A7-4B7E-8E86-A593F1B8C93A

Q33419580-2DB3B59F-5D4F-45A7-9C59-2A0F77F79065

Q33419580-330C864E-B3F7-46DD-B2DC-C67E5E0D7FCB

Q33419580-374B46DA-3E03-4116-884C-54278140BE24

Q33419580-3D779670-EDC6-4D01-BDCB-348669A11CA8

Q33419580-4F9529EB-7B34-4FE0-AF8E-C1D106187F32

Q33419580-5529E616-36EE-4B7C-96AD-23157F78244A

P304

Q33419580-2638272A-5E06-41C0-8764-34AABDB0F881

P31

Q33419580-EBDF39F2-B4C3-46A7-AE29-B8235AACE602

P356

Q33419580-CC53F034-E9AB-418C-951D-1327D667BDA9

P433

Q33419580-4CAB2F7B-DEA5-4B94-8236-8C131BF73E52

P478

Q33419580-79BE369B-D4D6-4633-B7BB-C2B3A0D9D5CF

P50

Q33419580-93B5DBBD-895F-4494-914A-CF03A4BC6366

Q33419580-E9E2E169-95BE-4886-B381-C96AF48F9E00

P577

Q33419580-B1FA94B7-6A9C-45EF-8CB2-F3F4B048EAC1

P698

Q33419580-D44FF603-5114-4A00-8024-E0A03F5B0542

P921

Q33419580-17A31A18-3B10-4F62-98FC-A86D3676247A

Q33419580-33D2F055-772E-47FB-A7F2-F921ADAB4563

Q33419580-6D0F083F-821D-4CC4-86EB-A1DE5BF834D9

P932

Q33419580-26F2D9FC-E87E-422A-8AE9-5C302E2323DB

P356

S1470-2045(14)71182-9

P1433

The Lancet Oncology

P1476

Ibrutinib for previously untre ...... : a phase 2, single-arm trial.

@en

P2093

Adrian Wiestner

http://www.w3.org/2001/XMLSchema#string

Andrew Lipsky

http://www.w3.org/2001/XMLSchema#string

Christian H Geisler

http://www.w3.org/2001/XMLSchema#string

Constance Yuan

http://www.w3.org/2001/XMLSchema#string

Diane C Arthur

http://www.w3.org/2001/XMLSchema#string

Georg Aue

http://www.w3.org/2001/XMLSchema#string

Gerald Marti

http://www.w3.org/2001/XMLSchema#string

Irina Maric

http://www.w3.org/2001/XMLSchema#string

Jade Jones

http://www.w3.org/2001/XMLSchema#string

Janet Valdez

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL

Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion.

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

P304

169-176

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1470-2045(14)71182-9

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Christian Geisler

Carsten Niemann

P577

2014-12-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25555420

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

4342187

http://www.w3.org/2001/XMLSchema#string